Gubra

Analyytikon kommentti24.08.2026 klo 12.36 -

Gubra: Roche's USD 2.3bn UCN2 deal sets a reference point for Gubra's own candidate

Hanmi Pharm announced this morning that it has entered into an exclusive licensing agreement with Genentech, part of the Roche Group, on its long-acting urocortin-2 (UCN2) analog, for obesity. This is the first large pharma transaction on a UCN2 asset, and it is the most direct external validation Gubra's GUB-UCN2 program has received to date

Gubra

Analyytikon kommentti20.08.2026 klo 09.00 -

Michael Friis

Gubra: H1 2026, strong clinical pipeline momentum and early signs of CRO recovery

Gubra reported H1 2026 results this morning under the heading of strong clinical pipeline momentum and business execution, and the CRO business is showing signs of bottoming out with management expressing some optimism going forward.

Gubra

Analyytikon kommentti28.07.2026 klo 09.50 -

Michael Friis

Gubra: UCN2 enters the clinic with an ambitious Phase 1/2a design and an R&D Day date

Gubra this morning announced the initiation of the first-in-human trial of GUB-UCN2, the company's wholly owned muscle-sparing obesity candidate, with the first participant having completed the first visit. The event confirms the FPFV timeline of H2 2026.

Gubra

Analyytikon kommentti16.07.2026 klo 08.49 -

Michael Friis

Gubra: Boehringer Ingelheim initiates Phase 2 of triple agonist, triggering EUR 10m milestone

Gubra today announced that its partner Boehringer Ingelheim has initiated Phase 2 clinical development of BI 3034701, a potential first-in-class triple GLP-1, GIP and NPY2 receptor agonist peptide, triggering EUR 10m in milestones.

Gubra